EGFR and non-small cell lung carcinoma: Van Veggel et al. reported four stage IV NSCLC patients with EGFR exon 20ins treated with afatinib (40 mg/d) and cetuximab (250-500 mg, q2w); 3/4 patients (Ser768_Asp770dup, Asn771_His773dup and Ala767_Val769dup) showed a partial response (PR), whereas the remaining (His773dup) showed stable disease (SD); the mPFS was 5.4 months (66).